Baidu
map

药品信息速递

订阅

MedSci主页 / 所有栏目 / 药品信息速递

Astellas的gilteritinib药物被评为孤儿药

2018-01-23 MedSci MedSci原创

Gilteritinib孤儿药
关注

Astellas实验性急性骨髓性白血病药物gilteritinib已被欧洲委员会授予孤儿药名称。这一决定表明，监管机构认为这种药物可能对罕见病患者有重大益处，其中每年在西欧确诊的新病例约有13，000例。Gilteritinib正在开发用于FLT3突变阳性复发或难治性AML的成人患者，这与特别不良的预后相关。最初通过与Kotobuki制药公司合作发现的药物目前正在III期试验中进行研究。Astel


Astellas实验性急性骨髓性白血病药物gilteritinib已被欧洲委员会授予孤儿药名称。

这一决定表明，监管机构认为这种药物可能对罕见病患者有重大益处，其中每年在西欧确诊的新病例约有13，000例。

Gilteritinib正在开发用于FLT3突变阳性复发或难治性AML的成人患者，这与特别不良的预后相关。
最初通过与Kotobuki制药公司合作发现的药物目前正在III期试验中进行研究。

Astellas肿瘤发展全球治疗领域负责人Steven Benner指出："我们非常感谢EMA承认罕见疾病患者的独特需求，并为gilteritinib在这些患者中的应用提供了一个潜在的支持途径。"

该药物在美国也有孤儿药地位。


此文系梅斯医学（MedSci)原创整理编译，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1668991, encodeId=196a166899128, content=<a href='/topic/show?id=f1cf802378' target=_blank style='color:#2F92EE;'>#Gilteritinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8023, encryptionId=f1cf802378, topicName=Gilteritinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=651326488537, createdName=jml2018, createdTime=Fri Sep 21 22:26:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711353, encodeId=3bde1e11353b4, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 24 01:26:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561950, encodeId=8963156195021, content=<a href='/topic/show?id=1f95289ea7' target=_blank style='color:#2F92EE;'>#Astellas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2897, encryptionId=1f95289ea7, topicName=Astellas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Jan 25 12:26:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281588, encodeId=52c728158805, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9d2256316, createdName=1217549fm29暂无昵称, createdTime=Wed Jan 24 13:11:11 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281484, encodeId=23e7281484ab, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9d2256316, createdName=1217549fm29暂无昵称, createdTime=Wed Jan 24 07:37:18 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281395, encodeId=f4852813953d, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jan 23 23:25:04 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281363, encodeId=770128136393, content=Astellas实验性急性骨髓性白血病药物gilteritinib已被欧洲委员会授予孤儿药名称., beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Jan 23 22:29:17 CST 2018, time=2018-01-23, status=1, ipAttribution=)]
    2018-09-21 jml2018

    #Gilteritinib#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1668991, encodeId=196a166899128, content=<a href='/topic/show?id=f1cf802378' target=_blank style='color:#2F92EE;'>#Gilteritinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8023, encryptionId=f1cf802378, topicName=Gilteritinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=651326488537, createdName=jml2018, createdTime=Fri Sep 21 22:26:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711353, encodeId=3bde1e11353b4, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 24 01:26:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561950, encodeId=8963156195021, content=<a href='/topic/show?id=1f95289ea7' target=_blank style='color:#2F92EE;'>#Astellas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2897, encryptionId=1f95289ea7, topicName=Astellas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Jan 25 12:26:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281588, encodeId=52c728158805, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9d2256316, createdName=1217549fm29暂无昵称, createdTime=Wed Jan 24 13:11:11 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281484, encodeId=23e7281484ab, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9d2256316, createdName=1217549fm29暂无昵称, createdTime=Wed Jan 24 07:37:18 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281395, encodeId=f4852813953d, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jan 23 23:25:04 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281363, encodeId=770128136393, content=Astellas实验性急性骨髓性白血病药物gilteritinib已被欧洲委员会授予孤儿药名称., beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Jan 23 22:29:17 CST 2018, time=2018-01-23, status=1, ipAttribution=)]
    2018-09-24 zhaojie88

    #AST#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1668991, encodeId=196a166899128, content=<a href='/topic/show?id=f1cf802378' target=_blank style='color:#2F92EE;'>#Gilteritinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8023, encryptionId=f1cf802378, topicName=Gilteritinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=651326488537, createdName=jml2018, createdTime=Fri Sep 21 22:26:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711353, encodeId=3bde1e11353b4, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 24 01:26:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561950, encodeId=8963156195021, content=<a href='/topic/show?id=1f95289ea7' target=_blank style='color:#2F92EE;'>#Astellas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2897, encryptionId=1f95289ea7, topicName=Astellas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Jan 25 12:26:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281588, encodeId=52c728158805, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9d2256316, createdName=1217549fm29暂无昵称, createdTime=Wed Jan 24 13:11:11 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281484, encodeId=23e7281484ab, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9d2256316, createdName=1217549fm29暂无昵称, createdTime=Wed Jan 24 07:37:18 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281395, encodeId=f4852813953d, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jan 23 23:25:04 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281363, encodeId=770128136393, content=Astellas实验性急性骨髓性白血病药物gilteritinib已被欧洲委员会授予孤儿药名称., beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Jan 23 22:29:17 CST 2018, time=2018-01-23, status=1, ipAttribution=)]
    2018-01-25 docwu2019

    #Astellas#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1668991, encodeId=196a166899128, content=<a href='/topic/show?id=f1cf802378' target=_blank style='color:#2F92EE;'>#Gilteritinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8023, encryptionId=f1cf802378, topicName=Gilteritinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=651326488537, createdName=jml2018, createdTime=Fri Sep 21 22:26:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711353, encodeId=3bde1e11353b4, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 24 01:26:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561950, encodeId=8963156195021, content=<a href='/topic/show?id=1f95289ea7' target=_blank style='color:#2F92EE;'>#Astellas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2897, encryptionId=1f95289ea7, topicName=Astellas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Jan 25 12:26:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281588, encodeId=52c728158805, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9d2256316, createdName=1217549fm29暂无昵称, createdTime=Wed Jan 24 13:11:11 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281484, encodeId=23e7281484ab, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9d2256316, createdName=1217549fm29暂无昵称, createdTime=Wed Jan 24 07:37:18 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281395, encodeId=f4852813953d, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jan 23 23:25:04 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281363, encodeId=770128136393, content=Astellas实验性急性骨髓性白血病药物gilteritinib已被欧洲委员会授予孤儿药名称., beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Jan 23 22:29:17 CST 2018, time=2018-01-23, status=1, ipAttribution=)]
    2018-01-24 1217549fm29暂无昵称

    henhao

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1668991, encodeId=196a166899128, content=<a href='/topic/show?id=f1cf802378' target=_blank style='color:#2F92EE;'>#Gilteritinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8023, encryptionId=f1cf802378, topicName=Gilteritinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=651326488537, createdName=jml2018, createdTime=Fri Sep 21 22:26:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711353, encodeId=3bde1e11353b4, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 24 01:26:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561950, encodeId=8963156195021, content=<a href='/topic/show?id=1f95289ea7' target=_blank style='color:#2F92EE;'>#Astellas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2897, encryptionId=1f95289ea7, topicName=Astellas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Jan 25 12:26:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281588, encodeId=52c728158805, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9d2256316, createdName=1217549fm29暂无昵称, createdTime=Wed Jan 24 13:11:11 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281484, encodeId=23e7281484ab, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9d2256316, createdName=1217549fm29暂无昵称, createdTime=Wed Jan 24 07:37:18 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281395, encodeId=f4852813953d, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jan 23 23:25:04 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281363, encodeId=770128136393, content=Astellas实验性急性骨髓性白血病药物gilteritinib已被欧洲委员会授予孤儿药名称., beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Jan 23 22:29:17 CST 2018, time=2018-01-23, status=1, ipAttribution=)]
    2018-01-24 1217549fm29暂无昵称

    henhao

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1668991, encodeId=196a166899128, content=<a href='/topic/show?id=f1cf802378' target=_blank style='color:#2F92EE;'>#Gilteritinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8023, encryptionId=f1cf802378, topicName=Gilteritinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=651326488537, createdName=jml2018, createdTime=Fri Sep 21 22:26:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711353, encodeId=3bde1e11353b4, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 24 01:26:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561950, encodeId=8963156195021, content=<a href='/topic/show?id=1f95289ea7' target=_blank style='color:#2F92EE;'>#Astellas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2897, encryptionId=1f95289ea7, topicName=Astellas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Jan 25 12:26:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281588, encodeId=52c728158805, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9d2256316, createdName=1217549fm29暂无昵称, createdTime=Wed Jan 24 13:11:11 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281484, encodeId=23e7281484ab, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9d2256316, createdName=1217549fm29暂无昵称, createdTime=Wed Jan 24 07:37:18 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281395, encodeId=f4852813953d, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jan 23 23:25:04 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281363, encodeId=770128136393, content=Astellas实验性急性骨髓性白血病药物gilteritinib已被欧洲委员会授予孤儿药名称., beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Jan 23 22:29:17 CST 2018, time=2018-01-23, status=1, ipAttribution=)]
    2018-01-23 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1668991, encodeId=196a166899128, content=<a href='/topic/show?id=f1cf802378' target=_blank style='color:#2F92EE;'>#Gilteritinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8023, encryptionId=f1cf802378, topicName=Gilteritinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=651326488537, createdName=jml2018, createdTime=Fri Sep 21 22:26:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711353, encodeId=3bde1e11353b4, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 24 01:26:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561950, encodeId=8963156195021, content=<a href='/topic/show?id=1f95289ea7' target=_blank style='color:#2F92EE;'>#Astellas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2897, encryptionId=1f95289ea7, topicName=Astellas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Jan 25 12:26:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281588, encodeId=52c728158805, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9d2256316, createdName=1217549fm29暂无昵称, createdTime=Wed Jan 24 13:11:11 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281484, encodeId=23e7281484ab, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9d2256316, createdName=1217549fm29暂无昵称, createdTime=Wed Jan 24 07:37:18 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281395, encodeId=f4852813953d, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jan 23 23:25:04 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281363, encodeId=770128136393, content=Astellas实验性急性骨髓性白血病药物gilteritinib已被欧洲委员会授予孤儿药名称., beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Jan 23 22:29:17 CST 2018, time=2018-01-23, status=1, ipAttribution=)]
    2018-01-23 有备才能无患

    Astellas实验性急性骨髓性白血病药物gilteritinib已被欧洲委员会授予孤儿药名称.

    0

相关资讯

Lancet Oncol：Gilteritinib可选择性抑制复发或难治性AML的FLT3突变

约三成的复发或难治性AML患者会出现FLT3突变。体外试验显示，gilteritinib可对FLT3选择性抑制，但是还没有人体试验数据。6月20日在线发表于Lancet Oncology上的一篇文章表示，FLT3突变的复发或难治性AML患者中，gilteritinib的安全性特征良好，应答持续时间长，总体生存结局令人鼓舞。

Lancet Oncol：Gilteritinib有效治疗复发或难治性急性髓性白血病

Gilteritinib在复发或难治性急性髓性白血病患者中表现出较高的安全性以及持续的FLT3抑制活性

Baidu
map
Baidu
map
Baidu
map